Cover Image
市場調查報告書

多發性硬化症:全球臨床實驗趨勢

Multiple Sclerosis Global Clinical Trials Review, H1, 2018

出版商 GlobalData 商品編碼 308781
出版日期 內容資訊 英文 940 Pages
訂單完成後即時交付
價格
Back to Top
多發性硬化症:全球臨床實驗趨勢 Multiple Sclerosis Global Clinical Trials Review, H1, 2018
出版日期: 2018年02月28日 內容資訊: 英文 940 Pages
簡介

本報告提供多發性硬化症治療藥相關之臨床實驗最新趨勢分析,提供您G7(主要7國)及E7(新興7國)的臨床實驗數量,受驗人數,並彙整有潛力的贊助商,臨床實驗主要參與企業和機關,有潛力的藥劑等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5國的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗上多發性硬化症的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗上多發性硬化症的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

多發性硬化症治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4815CTIDB

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 32
  • Prominent Drugs 33
  • Latest Clinical Trials News on Multiple Sclerosis 34
  • Feb 21, 2018: Oryzon to present at upcoming international conferences 34
  • Feb 02, 2018: Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting 34
  • Feb 01, 2018: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal 35
  • Jan 31, 2018: MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum 35
  • Jan 29, 2018: ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego 36
  • Jan 23, 2018: ORYZON to present at two US investor conferences 36
  • Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 37
  • Dec 18, 2017: Mabion with a new innovative indication in the treatment of multiple sclerosis for MabionCD20 37
  • Clinical Trial Profile Snapshots 38

Appendix 938

  • Abbreviations 938
  • Definitions 938
  • Research Methodology 939
  • Secondary Research 939
  • About GlobalData 940
  • Contact Us 940
  • Source 940

List of Tables

List of Tables

  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2018* 8
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12
  • Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13
  • Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2018* 14
  • Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 15
  • Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 16
  • Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 18
  • Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
  • Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
  • Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 21
  • Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2018* 24
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 27
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 28
  • Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 29
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 30
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 32
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33

List of Figures

List of Figures

  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
  • Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12
  • Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13
  • Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14
  • Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 15
  • Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 16
  • Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 17
  • Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
  • Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
  • Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 21
  • Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
  • Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 27
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 28
  • Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 29
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 30
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 32
  • Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33
  • GlobalData Methodology 939
Back to Top